ISSN: **3107-6513**

Management Strategies in Refractory Adult Immune Thrombocytopenia

Bouchnafati Sanaa[#1]

[#] *Department of Internal Medicine, Provincial Hospital of Ouarzazate, Morocco*

[1]sanaa.bouchnafati@gmail.com

Abstract

Refractory immune thrombocytopenia (ITP) in adults remains a therapeutic challenge, affecting 3–8% of patients and associated with significant bleeding risk, treatment-related toxicity, and impaired quality of life. This narrative review synthesizes contemporary evidence on the stepwise management of refractory ITP, emphasizing the transition from risk-adapted early intervention to advanced multimodal strategies. Key principles include early identification of high-risk patients using clinical, therapeutic response, and biological predictors, prompt diagnostic reappraisal to exclude secondary causes, and individualized sequencing of third-line and emerging therapies.

Current options encompass fostamatinib, Bruton tyrosine kinase (BTK) inhibitors, complement inhibitors, FcRn antagonists, and autologous hematopoietic stem cell transplantation in highly selected cases. Integration of TPO-RAs with immunosuppression, careful management of bleeding risk, and consideration of comorbidities are central to optimizing outcomes. Future directions point toward biomarker-driven therapy and novel agents targeting specific pathogenic pathways.

Keywords: *Refractory immune thrombocytopenia; difficult-to-treat ITP; TPO-RA failure; personalized therapy; fostamatinib; BTK inhibitors; FcRn antagonists; risk stratification.*

I. INTRODUCTION

While most adults with primary immune thrombocytopenia (ITP) achieve adequate platelet counts with first- and second-line therapies, a subset develops refractory disease characterized by persistent severe thrombocytopenia, clinically relevant bleeding, or dependence on toxic treatments despite multiple lines of therapy. Refractory ITP carries substantial morbidity and requires a structured, mechanism-informed approach.

Building on predictive models that identify patients at risk of progression (adult onset, insidious presentation, poor initial corticosteroid/IVIg response, ANA positivity, low IPF, etc.), this review focuses on practical management strategies once refractoriness is established. The goal is to minimize bleeding, reduce treatment burden, and improve long-term outcomes through personalized, stepwise escalation.

II. DIAGNOSTIC REAPPRAISAL: THE ESSENTIAL FIRST STEP

First, confirm that you have the correct template for your paper size. This template has been tailored for output on the A4 paper size True refractoriness cannot be declared until secondary ITP and non-immune thrombocytopenias have been rigorously excluded. Recommended evaluations include:

- Bone marrow examination (especially in older patients or those with other cytopenias).
- Extended autoimmunity workup (ANA, anti-dsDNA, antiphospholipid antibodies, complement levels).
- Lymphoproliferative disorder screening (flow cytometry, imaging, serum protein electrophoresis).
- Drug-induced, infection-related, and inherited thrombocytopenia mimics.

Persistent diagnostic uncertainty warrants hematology consultation and, when appropriate, repeat bone marrow assessment.

III. RISK STRATIFICATION TO GUIDE INTENSITY OF THERAPY

Patients with refractory ITP are heterogeneous. High-risk features justifying aggressive intervention include:

- History of severe bleeding (intracranial, gastrointestinal).
- Multiple prior treatment failures (corticosteroids + IVIg + ≥1 TPO-RA).
- Comorbidities increasing bleeding or infection risk.
- Biological markers suggestive of prominent hypoproduction or complement/T-cell driven pathology.

Low-burden patients may benefit from watchful waiting with supportive measures (tranexamic acid, careful avoidance of antiplatelet agents).

ISSN: **3107-6513**

IV.OPTIMIZATION OF EXISTING THERAPIES

A. Thrombopoietin Receptor Agonists (TPO-RAs)

Even after initial failure, switching between eltrombopag and romiplostim (or trying avatrombopag) can restore response in a proportion of patients. Combination with low-dose corticosteroids or immunosuppressants (mycophenolate mofetil, azathioprine) often improves durability.

B. Rituximab

Although response rates are modest in heavily pretreated patients (~20–40%), retreatment or combination with TPO-RAs may be considered in B-cell driven disease.

V. THIRD-LINE AND EMERGING TARGETED THERAPIES

C. Spleen Tyrosine Kinase (SYK) Inhibition – Fostamatinib

Fostamatinib has demonstrated efficacy in patients failing TPO-RAs and rituximab, with overall response rates around 40–50%.

D. Bruton Tyrosine Kinase (BTK) Inhibitors

Agents such as rilzabrutinib show promising data in refractory ITP.

E. Neonatal Fc Receptor (FcRn) Antagonists

Efgartigimod and others accelerate IgG catabolism and show high response rates in multi-refractory ITP.

F. Complement Inhibition

Sutimlimab and other complement blockers are under investigation.

VI. SUPPORTIVE CARE AND BLEEDING MANAGEMENT

- Platelet transfusions for life-threatening hemorrhage (combined with IVIg or TPO-RAs).
- Antifibrinolytics (tranexamic acid).
- Vaccination and infection prophylaxis.

VII. PROPOSED ALGORITHM FOR REFRACTORY ITP

- Confirm refractoriness + exhaustive diagnostic re-evaluation.
- Optimize/switch TPO-RA ± low-dose immunosuppression.
- Add fostamatinib or BTK inhibitor.
- Consider FcRn antagonists or complement inhibitors.
- Multidisciplinary discussion for experimental options.

VIII. DISCUSSION

The management of refractory adult immune thrombocytopenia has undergone substantial evolution over the past decade, shifting from a largely empirical approach relying on splenectomy and broad immunosuppression to a more nuanced, mechanism-based strategy. This transition has been driven by a deeper understanding of ITP pathophysiology and the advent of targeted therapies that address specific disease pathways—Fc-mediated clearance, complement activation, autoantibody production, and impaired megakaryopoiesis.

A key insight emerging from recent registry data (such as CARMEN-France) is the marked heterogeneity of refractory ITP. Not all “refractory” patients are equivalent: some exhibit predominant peripheral destruction, others significant production defects, while a subset shows overlapping complement or T-cell cytotoxicity. This biological diversity explains why a sequential “one-size-fits-all” algorithm often fails and underscores the importance of integrating predictive factors identified in companion analyses—particularly early corticosteroid resistance, ANA positivity, low immature platelet fraction (IPF), and elevated thrombopoietin levels—into therapeutic decision-making from the outset.

The availability of multiple second- and third-line options now allows for more rational drug sequencing. For instance, patients with suspected prominent Fc-receptor mediated clearance may benefit earlier from fostamatinib or FcRn antagonists, whereas those with evidence of B-cell driven autoimmunity could be candidates for optimized rituximab-based regimens or emerging BTK inhibitors such as rilzabrutinib. The latter class is particularly promising due to its oral administration, rapid onset of action, and more favorable safety profile compared with traditional immunosuppressants. Similarly, complement inhibitors (e.g., sutimlimab) open new therapeutic avenues for the subgroup of patients in whom complement activation plays a major role.

Nevertheless, several challenges persist. First, the lack of widely validated biomarkers capable of reliably predicting response to individual agents limits true personalization. Most current decisions remain based on clinical phenotype and trial-and-error, which can lead to prolonged exposure to ineffective or toxic treatments. Second, real-world data reveal that even with novel agents, sustained responses are achieved in only 40–60% of heavily pretreated patients, highlighting the need for combination strategies. Triple or quadruple therapy (e.g., TPO-RA + fostamatinib + low-dose immunosuppression) is increasingly used in expert centers but lacks robust prospective validation regarding long-term safety and efficacy.

Economic and access considerations also play a critical role, particularly in middle-income settings. Many of the newest agents remain expensive and unavailable in numerous countries, forcing clinicians to rely on older, less targeted options with higher cumulative toxicity (corticosteroids, azathioprine, cyclophosphamide). This reality emphasizes the importance of health economics research and the development of affordable biosimilars or generic versions of key molecules.

From a research perspective, the field is moving toward integrated risk models that combine clinical trajectory, treatment response dynamics, immune profiling (lymphocyte subsets, cytokine signature, autoantibody specificity), and emerging molecular markers (e.g., gene expression profiles of

ISSN: **3107-6513**

megakaryocytes or platelets). Machine learning applied to large international registries holds considerable promise for generating clinically actionable decision-support tools. Prospective biomarker-driven trials, such as those evaluating FcRn antagonists or BTK inhibitors in predefined mechanistic subgroups, are urgently needed to move beyond the current empiricism.

Finally, the psychological and quality-of-life burden of refractory ITP should not be underestimated. Chronic fatigue, fear of bleeding, treatment side effects, and frequent medical visits significantly impair patients' daily functioning. Future management strategies must incorporate patient-reported outcomes as key endpoints and promote multidisciplinary care involving hematologists, psychologists, and social workers.

In summary, while important progress has been made, refractory ITP continues to represent both a clinical challenge and a scientific opportunity. By combining early risk stratification, rigorous diagnostic reappraisal, and intelligent use of the expanding therapeutic arsenal, clinicians can meaningfully improve outcomes for this difficult-to-treat population. Collaborative, multicenter efforts will be essential to refine personalized algorithms and ultimately reduce the proportion of patients who remain truly refractory.

IX.CONCLUSION AND RECOMMENDATIONS

Effective management requires a proactive, mechanism-based approach. Early risk stratification and timely introduction of targeted therapies can substantially improve outcomes.

X.REFERENCES

[1] Moulis G, et al. Difficult-to-treat primary immune thrombocytopenia in adults. Br J Haematol. 2024.

[2] Provan D, et al. Updated international consensus report on ITP. Blood Adv. 2019.

[3] Neunert C, et al. ASH 2019 guidelines. Blood Adv. 2019.

[4] Bussel JB, et al. Fostamatinib for persistent and chronic ITP.

[5] Bussel JB, et al. Recent data on rilzabrutinib and efgartigimod.